Kurzbeschreibung (Abstract)

Stereotactic body image guided radiation therapy (SBRT) shows excellent results for the local control of early stage lung cancer.
However, not all patients are eligible for SBRT, and advanced stage treatment is less successful and often associated with severe side effects.
Scanned carbon ion therapy (PT) can deliver more conformal dose likely benefiting these patient groups.

Therefore an \textit{in silico} trial was conducted on early and advanced stage patients to identify potential advantages of PT.
The patients were treated with SBRT at Champalimaud Center for the Unknown, Lisbon (Portugal). PT plans were simulated on 4DCTs,
and rescanning was investigated for motion mitigation in 4D-dose calculations. A dedicated strategy for 4D intensity modulated particle therapy (IMPT)
was developed and applied for advanced stage patients with multiple lesions. For clinically valid and reliable results the deformable
image registration - necessary for 4D-dose calculation - a quality assurance tool was developed and applied in the study.

The results showed that target coverage was comparable in SBRT and PT, while PT delivered significantly lower doses to
most critical structures, especially the heart, lungs, and esophagus. A highly complex case of advanced stage lung cancer could be treated
in a single fraction of 24~Gy with PT, while SBRT could not deliver the full ablative dose treatment due to an excessive heart dose.
The mean heart dose was reduced from 10~Gy to 0.8~Gy with PT for this specific patient.

In Silico Comparison of Photons versus Carbon Ions in Single Fraction Therapy of Lung Cancer

Sprache:

Englisch

Kurzbeschreibung (Abstract):

Stereotactic body image guided radiation therapy (SBRT) shows excellent results for the local control of early stage lung cancer.
However, not all patients are eligible for SBRT, and advanced stage treatment is less successful and often associated with severe side effects.
Scanned carbon ion therapy (PT) can deliver more conformal dose likely benefiting these patient groups.

Therefore an \textit{in silico} trial was conducted on early and advanced stage patients to identify potential advantages of PT.
The patients were treated with SBRT at Champalimaud Center for the Unknown, Lisbon (Portugal). PT plans were simulated on 4DCTs,
and rescanning was investigated for motion mitigation in 4D-dose calculations. A dedicated strategy for 4D intensity modulated particle therapy (IMPT)
was developed and applied for advanced stage patients with multiple lesions. For clinically valid and reliable results the deformable
image registration - necessary for 4D-dose calculation - a quality assurance tool was developed and applied in the study.

The results showed that target coverage was comparable in SBRT and PT, while PT delivered significantly lower doses to
most critical structures, especially the heart, lungs, and esophagus. A highly complex case of advanced stage lung cancer could be treated
in a single fraction of 24~Gy with PT, while SBRT could not deliver the full ablative dose treatment due to an excessive heart dose.
The mean heart dose was reduced from 10~Gy to 0.8~Gy with PT for this specific patient.